SCHEMBL2351909

SCHEMBL2351909

CCC(C)P(=O)(O)C(CCN)c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
ACP3 P15309 3/20 0.43
HRH1 P35367 1/20 0.42
POLB P06746 1/20 0.40
GABBR2 O75899 1/20 0.40
GABBR1 Q9UBS5 1/20 0.40
ANPEP P15144 1/20 0.39
ALDH1A1 P00352 1/20 0.37
LMNA P02545 1/20 0.37
TAAR1 Q96RJ0 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2172087 0.86 ACP3 (0.44) ACP3POLBANPEPALDH1A1LMNA
SCHEMBL2352039 0.86 ACP3 (0.46) ACP3HRH1POLBANPEPALDH1A1
SCHEMBL2172115 0.80 FFAR1 (0.43) ACP3POLBGABBR2GABBR1LMNA
SCHEMBL2352723 0.80 ACP3 (0.46) ACP3HRH1POLBANPEP
Hydrochloric Acid SCHEMBL2392993 0.78 ACP3 (0.45) ACP3HRH1POLB
SCHEMBL2392797 0.78 ACP3 (0.45) ACP3HRH1POLBANPEP
SCHEMBL2352708 0.77 ACP3 (0.44) ACP3HRH1ANPEPALDH1A1TAAR1
SCHEMBL2354091 0.77 ACP3 (0.44) ACP3HRH1POLB
SCHEMBL30481345 0.75 ACP3 (0.39) ACP3POLBANPEPLMNA
SCHEMBL30481471 0.75 ACP3 (0.39) ACP3POLBANPEPLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9035088-B2 Method for producing mono-aminofunctionalized dialkylphosphinic acids and esters and salts thereof by means of acrylnitriles and use thereof CLARIANT FINANCE (BVI) LIMITED (VG) 2015-05-19 US disclosed
CN-102186866-B Method for producing mono amino-functionalised dialkylphosphinite acids esters and salts and use thereof CLARIANT INT LTD 2015-04-29 CN disclosed
EP-2373666-B1 METHOD FOR PRODUCING MONO-AMINOFUNCTIONALIZED DIALKYLPHOSPHINIC ACIDS AND ESTERS AND SALTS THEREOF BY MEANS OF ACRYLNITRILES AND USE THEREOF CLARIANT FINANCE BVI LTD (VG) 2014-09-24 EP disclosed
US-8604232-B2 Method for producing monoamino-functionalised dialkylphosphinite acids esters and salts and use thereof CLARIANT FINANCE (BVI) LIMITED (VG) 2013-12-10 US disclosed
EP-2352741-B1 METHOD FOR PRODUCING MONO AMINO-FUNCTIONALISED DIALKYLPHOSPHINITE ACIDS ESTERS AND SALTS AND USE THEREOF CLARIANT INT LTD (CH) 2013-08-28 EP disclosed
EP-2373666-A1 METHOD FOR PRODUCING MONO-AMINOFUNCTIONALIZED DIALKYLPHOSPHINIC ACIDS AND ESTERS AND SALTS THEREOF BY MEANS OF ACRYLNITRILES AND USE THEREOF Clariant Finance (BVI) Limited (VG) 2011-10-12 EP disclosed
US-20110213078-A1 Method for Producing Mono-Aminofunctionalized Dialkylphosphinic Acids and Esters and Salts Thereof by Means of Acrylnitriles and Use Thereof CLARIANT FINANCE (BVI) LIMITED (VG) 2011-09-01 US disclosed
US-20110213061-A1 Method for Producing Mono-Aminofunctionalized Dialkylphosphinic Acids and Esters and Salts Thereof and Use Thereof CLARIANT FINANCE (BVI) LIMITED (VG) 2011-09-01 US disclosed
US-20110213079-A1 Method for Producing Monoamino-Functionalised Dialkylphosphinite Acids Esters and Salts and Use Thereof CLARIANT FINANCE (BVI) LIMITED (VG) 2011-09-01 US disclosed
EP-2352741-A1 METHOD FOR PRODUCING MONO AMINO-FUNCTIONALISED DIALKYLPHOSPHINITE ACIDS ESTERS AND SALTS AND USE THEREOF Clariant International Ltd. (CH) 2011-08-10 EP disclosed
WO-2010051892-A1 METHOD FOR PRODUCING MONO-AMINOFUNCTIONALIZED DIALKYLPHOSPHINIC ACIDS AND ESTERS AND SALTS THEREOF BY MEANS OF ACRYLNITRILES AND USE THEREOF CLARIANT INTERNATIONAL LTD (CH) 2010-05-14 WO disclosed
WO-2010051894-A1 METHOD FOR PRODUCING MONO AMINO-FUNCTIONALISED DIALKYLPHOSPHINITE ACIDS ESTERS AND SALTS AND USE THEREOF CLARIANT INTERNATIONAL LTD (CH) 2010-05-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110213078-A1 Method for Producing Mono-Aminofunctionalized Dialkylphosphinic Acids and Esters and Salts Thereof by Means of Acrylnitriles and Use Thereof AOC2, AOC3, DAO ACP3 423/4885HRH1 552/4885POLB 1420/4885
US-20110213079-A1 Method for Producing Monoamino-Functionalised Dialkylphosphinite Acids Esters and Salts and Use Thereof DAO, HAO2, AOC1 ACP3 627/4885HRH1 251/4885POLB 1480/4885
US-20110213061-A1 Method for Producing Mono-Aminofunctionalized Dialkylphosphinic Acids and Esters and Salts Thereof and Use Thereof HAO2, ACSL1, ACSL3 ACP3 970/4885HRH1 328/4885POLB 1736/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.